Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Codexis, Novartis Ink Tech Transfer and License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Codexis, Novartis Ink Tech Transfer and License Agreement

Novartis to leverage CodeEvolver protein engineering platform technology develop performance enzymes for use in manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Codexis, Inc. has signed a CodeEvolver platform agreement with Novartis under which Codexis has granted a non-exclusive license to its CodeEvolver protein engineering platform technology to Novartis to develop performance enzymes for use in manufacturing pharmaceutical products. Upon completion of the technology transfer, the CodeEvolver protein engineering platform will be located at a Novartis site.
 
Novartis will pay Codexis an upfront payment, milestone payments upon the satisfactory completion of technology transfer and payments for improvements to the CodeEvolver platform technology. Also, Codexis will be eligible to receive payments for active pharmaceutical ingredients manufactured with enzymes developed by Novartis using the CodeEvolver technology. Codexis also receives certain rights for future purchases of enzymes developed and sourced by Novartis using the CodeEvolver technology.
 
“Novartis has been a highly valued Codexis customer for nearly a decade, and we’ve been very pleased to see the accelerating and widening of our R&D collaborations together especially over the past several years. Taking this next step to bring our CodeEvolver® technology in-house, Novartis is the latest leading pharmaceutical company to validate the very wide applicability of enzymatic catalysis across its extensive small molecule drug pipeline,” said Codexis president and chief executive officer, John Nicols. “We look forward to serving and deepening our relationship with Novartis in this new chapter from here.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics